CCCC C4 THERAPEUTICS

Health Care · Russell 2000

Next earnings: not announced yet

What 12 analyst firms say about C4 THERAPEUTICS: their latest ratings, price targets and how far the stock is from them. How it works

3.10 USD+0.15 (+5.08%) today

Price as of 6 Nov 16:00 ET

Analyst window: Latest analyst report within last 1 year

Analyst view · last 1Y

+369.5%to the avg target 14.56 USD+11.46 USD

Buy 10 · Hold 1 · Sell 0

11 rated views · 12 analyst/firm records · 12 firms

Latest report28 Oct 2026avg report date 21 Jul

Target rangePrice is below every target

now 3.10

Radar score

Russell 2000 · Top Picks · 6MNot scored · Price below 5 USD
Russell 2000 · Safest consensus · 6MNot scored · Price below 5 USD

Recent analyst activity · last 90 days

Our tracked history has 6 reports on CCCC from 6 analyst firms in the last 90 days (12 firms in the past year).

Comparing each firm's latest target with its previous one: 5 have their first observed target in the past year.

Last 1 year. Latest opinion per identifiable analyst within the last 1 year. BUY / HOLD / SELL each count one current analyst vote; unnamed firm records are a fallback.

Firm	Analyst	Latest rating	Report date	Latest target (USD)
Barclays	Etzer Darout	Buy	3 Aug 2026	7.00 USD
Brookline Capital	Unnamed analyst	Buy	23 Feb 2026	30.00 USD
Brookline Capital Markets	Leah R Cann	Buy	11 Aug 2026	30.00 USD
Evercore ISI	Gavin Clark-Gartner	Buy	1 Jun 2026	12.00 USD
Guggenheim	Bradley P Canino	Buy	18 Sep 2026	7.00 USD
Jefferies	Akash Tewari	Buy	1 Apr 2026	14.00 USD
JPMorgan	Anupam Rama	Buy	9 Oct 2026	10.00 USD
Lake Street Capital Markets	Chad Messer	Buy	28 Oct 2026	11.00 USD
TD Cowen	Tyler Van Buren	Buy	15 Jun 2026	—
Weiss Ratings	Unnamed analyst	—	15 Oct 2026	—
Wells Fargo	Derek C Archila	Buy	26 Aug 2026	10.00 USD
Data feed RESEARCH	Research Team	Hold	15 Jun 2026	—

Partial coverage · checked 6 Nov (6 Nov 2026, 06:58 ET). Some research records could not be refreshed. Cached records retained. Prices stream live during the US session; otherwise stored prices delayed about 15 minutes. A summary of analyst opinion, not investment advice.